Barclays Maintains a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT
Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the best strong buy penny stocks to buy now.
Relay Therapeutics Inc. (RLAY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Point72 Asset Management Steve Cohen | 13,445,704 | $46,522,136 | +25% | 0.09% |
| 2. | Commodore Capital Egen Atkinson And Michael Kramarz | 13,350,000 | $46,191,000 | 3.26% | |
| 3. | Casdin Capital Eli Casdin | 11,398,574 | $39,439,066 | +26% | 3.59% |
| 4. | Tang Capital Management Kevin C. Tang | 8,068,058 | $27,915,481 | 1.41% | |
| 5. | Kynam Capital Derrick Tang | 2,887,014 | $9,989,068 | -6% | 1.08% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 25,000 | $500,000.00 | 403,082 | 2020-07-20 | Filing | |
| $20.00 | 25,000 | $500,000.00 | 1,021,952 | 2020-07-20 | Filing | |
| $20.00 | 25,000 | $500,000.00 | 25,000 | 2020-07-20 | Filing | |
| $20.00 | 25,000 | $500,000.00 | 25,000 | 2020-07-20 | Filing | |
| $20.00 | 10,000 | $200,000.00 | 10,000 | 2020-07-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.68 | 15,724 | $57,864.32 | 377,998 | 2025-07-29 | Filing | |
| $3.74 | 1,359 | $5,082.66 | 393,722 | 2025-07-28 | Filing | |
| $3.68 | 18,380 | $67,638.40 | 335,295 | 2025-07-29 | Filing | |
| $3.74 | 1,701 | $6,361.74 | 353,675 | 2025-07-28 | Filing | |
| $3.68 | 26,701 | $98,259.68 | 552,720 | 2025-07-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 27,904,963 | $96,551,172 | 0.77% | |
| 2. | 13,954,486 | $48,282,522 | 0% | |
| 3. | 9,379,851 | $32,454,285 | 0% | |
| 4. | 8,230,870 | $28,478,810 | 0.63% | |
| 5. | 5,202,791 | $18,001,657 | 0% |
News See All
10 Best Strong Buy Penny Stocks to Buy Now
On July 28, Alan Rechtschaffen, UBS Global Wealth senior portfolio manager, appeared on CNBC’s ‘Money Movers’ to talk about the markets, his Fed outlook, and more.
Barclays Reiterates a Buy Rating on Relay Therapeutics (RLAY)
Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the best biotech penny stocks to buy right now.
14 Best Biotech Penny Stocks to Buy Right Now
He acknowledged that biotech has been a “super tough sector” either way, as there are hundreds of publicly traded stocks that do not add up to anything in aggregate.
BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT
Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts.
13 Best Long-Term Penny Stocks to Buy According to Analysts
On June 18, Société Générale's Subadra Rajappa appeared on CNBC to talk about her expectations from the Fed.
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory
We came across a bullish thesis on Relay Therapeutics, Inc. (RLAY) on Steve Wagner’s Substack. In this article, we will summarize the bulls’ thesis on RLAY. Relay Therapeutics, Inc.
Relay Therapeutics' RLY-2608 Shows Promising 11-Month PFS in Breast Cancer
On Monday, Relay Therapeutics Inc.
10 Best Low Priced Biotech Stocks to Buy Now
On May 8, Michael Yee, Senior Biotech Analyst at Jefferies, appeared on CNBC to discuss how tariffs and policy risks are pressuring the biotech industry, while simultaneously iterating that low valuations...
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory
We came across a bullish thesis on Relay Therapeutics, Inc. (RLAY) on Substack by Steve Wagner. In this article, we will summarize the bulls’ thesis on RLAY. Relay Therapeutics, Inc.
Billionaire Hedge Funds
